Femasys Inc. announced the first commercial procedure using its FemaSeed intratubal insemination product. FDA-Cleared FemaSeed is a revolutionary approach to enhancing fertilization, as a cost-effective primary therapeutic choice that carries notably reduced risks compared to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | -3.62% | -4.32% | +36.41% |
May. 09 | Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.41% | 30.5M | |
-4.98% | 181B | |
+2.84% | 112B | |
-2.68% | 67.92B | |
+4.53% | 50.1B | |
+8.00% | 44.27B | |
+9.39% | 40.41B | |
+25.30% | 31.95B | |
-0.17% | 25.82B | |
+17.27% | 25.29B |
- Stock Market
- Equities
- FEMY Stock
- News Femasys Inc.
- Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution